A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of
E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux
disease in a multicenter, randomized, double-blind, comparative study.